ISCK03

CAS No. 945526-43-2

ISCK03( ISCK 03 | ISCK-03 )

Catalog No. M16771 CAS No. 945526-43-2

A specific c-Kit inhibitor that inhibits c-kit phosphorylation in vitro and SCF-induced c-kit phosphorylation in human melanoma cells.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 30 In Stock
5MG 47 In Stock
10MG 77 In Stock
25MG 164 In Stock
50MG 281 In Stock
100MG 478 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    ISCK03
  • Note
    Research use only, not for human use.
  • Brief Description
    A specific c-Kit inhibitor that inhibits c-kit phosphorylation in vitro and SCF-induced c-kit phosphorylation in human melanoma cells.
  • Description
    A specific c-Kit inhibitor that inhibits c-kit phosphorylation in vitro and SCF-induced c-kit phosphorylation in human melanoma cells; also inhibits p44/42 ERK mitogen-activated protein kinase (MAPK) phosphorylation, does not inhibit HGF-induced phosphorylation of p44/42 ERK proteins; induces the dose-dependent depigmentation of newly regrown hair, promotes the depigmentation of UV-induced hyperpigmented spots in vivo; orally acitve.
  • In Vitro
    Pretreatment of 501mel cells with ISCK03 inhibits SCF-induced c-kit phosphorylation dose dependently. ISCK03 also inhibits p44/42 ERK mitogen-activated protein kinase (MAPK) phosphorylation, which is known to be involved in SCF/c-kit downstream signaling. However ISCK03 does not inhibit hepatocyte growth factor (HGF)-induced phosphorylation of p44/42 ERK proteins. ISCK03, a tyrosine kinase inhibitor specific to KIT, prevents survival of CCDC26-KD cells under low-serum conditions. All treated cells exhibits sensitivity to ISCK03 in a dose-dependent manner. After ISCK03 treatment, the survival of KD cells is suppressed to the same level as that of non-KD cells. Conversely, ISCK03 treatment has limited effects on the growth of control K562 and KD clone 3–4 cells under high-serum concentration conditions.
  • In Vivo
    Oral administration of ISCK03 induces the dose-dependent depigmentation of newly regrown hair, and this is reversed with cessation of ISCK03 treatment. The topical application of ISCK03 promotes the depigmentation of UV-induced hyperpigmented spots. Fontana-Masson staining analysis shows epidermal melanin is diminished in spots treated with ISCK03.
  • Synonyms
    ISCK 03 | ISCK-03
  • Pathway
    Angiogenesis
  • Target
    c-Kit
  • Recptor
    c-Kit
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    945526-43-2
  • Formula Weight
    355.45394
  • Molecular Formula
    C19H21N3O2S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 38 mg/mL
  • SMILES
    O=S(N(C1=CC=C(C(C)(C)C)C=C1)C2=CC=C(N3C=CN=C3)C=C2)=O
  • Chemical Name
    Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[4-(1H-imidazol-1-yl)phenyl]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Na YJ, et al. Biochem Pharmacol. 2007 Sep 1;74(5):780-6. 2. Kamlah F, et al. Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1541-9. 3. Hirano T, et al. Mol Cancer. 2015 Apr 19;14:90.
molnova catalog
related products
  • CHMFL-KIT-031

    CHMFL-KIT-031 is a highly selective KIT kinase primary V559D mutant inhibitor with IC50/Kd of 28/266 nM.

  • AZD2932

    AZD2932 is a new series of quinazoline ether inhibitor which potently inhibits VEGFR-2 and PDGFR with IC50s of 4 nM/8 nM/ 7 nM for PDGFRβ/VEGFR-2/Flt-3.

  • CP-673451

    CP-673451 is a selective inhibitor of PDGFRα/β with IC50 of 10 nM/1 nM.